aTyr Pharma, Inc. Aktie News
1,60 $
0,63 %
gestern
Nasdaq,
2. Mai, 22:00 Uhr
tracken
aTyr Pharma, Inc. Aktie News
Neutral
GlobeNewsWire
●
etwa 16 Stunden alt
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments.
Neutral
GlobeNewsWire
●
etwa ein Monat alt
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024. Details of the conferences appear be...
Positiv
InvestorPlace
●
etwa ein Monat alt
When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?
Neutral
Seeking Alpha
●
etwa 2 Monate alt
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™.
Neutral
GlobeNewsWire
●
2 Monate alt
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14...
Neutral
GlobeNewsWire
●
2 Monate alt
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.
Positiv
InvestorPlace
●
3 Monate alt
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in the financial markets, we can always identify good investment opportunities that allow us to add value to our portfolio and our wealth.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
